Get the Stockscreener App
33.00
0.12%
0.04
After Hours:
33.01
0.010
+0.03%
Harrow Inc stock is traded at $33.00, with a volume of 681.73K.
It is up +0.12% in the last 24 hours and down -15.69% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
See More
Previous Close:
$32.96
Open:
$33.39
24h Volume:
681.73K
Relative Volume:
0.81
Market Cap:
$1.23B
Revenue:
$272.30M
Net Income/Loss:
$-5.14M
P/E Ratio:
-201.83
EPS:
-0.1635
Net Cash Flow:
$42.76M
1W Performance:
+5.74%
1M Performance:
-15.69%
6M Performance:
-15.19%
1Y Performance:
+28.21%
1-Day Range:
$32.19
$33.39
1-Week Range:
$30.02
$33.39
52-Week Range:
$25.21
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
33.00 | 1.23B | 272.30M | -5.14M | 42.76M | -0.1635 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Harrow (HROW) Is Up 6.8% After Reaffirming 2026 Revenue Outlook Despite Wider Q1 LossesWhat's Changed - simplywall.st
Harrow Inc (HROW) Shares Surge 6.8% -- What GF Score of 82 Tells Investors - GuruFocus
Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism - Insider Monkey
Harrow: Demand Keeps It Interesting, Valuation Keeps It A Hold - Seeking Alpha
Harrow, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HROW) 2026-05-19 - Seeking Alpha
Harrow director Lauren Silvernail buys $31,000 in company stock By Investing.com - Investing.com Nigeria
Harrow director Adrienne Graves buys $31,070 in company stock By Investing.com - Investing.com Nigeria
Harrow director Lauren Silvernail buys $31,000 in company stock - Investing.com India
Insider Buying: Adrienne Graves Acquires Shares of Harrow Inc (H - GuruFocus
5 Best Small Cap Pharma Stocks to Buy Right Now - Insider Monkey
Harrow (HROW) director Adrienne Graves buys 1,000 shares at $31.07 - Stock Titan
Harrow (HROW) director purchases 1,000 common shares at $31.00 price - Stock Titan
Harrow projects $71M-$81M Q2 revenue while reaffirming $350M-$365M 2026 outlook - MSN
[Form 4] HARROW, INC. Insider Trading Activity - Stock Titan
Mark Baum Buys Handful Of Shares In Harrow - Yahoo Finance
Harrow’s TRIESENCE Phase 3 Milestone Adds New Dimension To Growth Story - Sahm
Harrow Stock (HROW) Opinions on Q1 Earnings and Insider Buying - Quiver Quantitative
Harrow (HROW) Executives Make Notable Stock Purchases - GuruFocus
Why Harrow (HROW) Narrative Is Shifting As Analysts Recut Targets Yet Stay Positive - Yahoo Finance
Insider Buying: Mark Baum Acquires Additional Shares of Harrow I - GuruFocus
Harrow Insider Bought Shares Worth $302,000, According to a Recent SEC Filing - Moomoo
Harrow, Inc. CEO Mark L. Baum buys $302,000 in common stock - Investing.com India
Harrow president and CFO Andrew Boll buys $104,650 in stock By Investing.com - Investing.com Australia
Harrow president and CFO Andrew Boll buys $104,650 in stock - Investing.com India
Harrow, Inc. CEO Mark L. Baum buys $302,000 in common stock By Investing.com - Investing.com South Africa
Harrow (HROW) CEO Mark Baum acquires 10,000 shares in open-market buy - Stock Titan
Harrow (NASDAQ: HROW) CFO adds 3,500 shares in open-market buy - Stock Titan
Harrow Inc (HROW) Shares Surge 3.5% -- What GF Score of 82 Tells Investors - GuruFocus
B. Riley Securities Maintains Harrow(HROW.US) With Buy Rating, Cuts Target Price to $60 - Moomoo
B. Riley Adjusts Price Target on Harrow to $60 From $65, Maintains Buy Rating - Moomoo
The Harrow, Inc. (NASDAQ:HROW) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance
Why Harrow (HROW) Is Down 25.9% After Q1 Miss And Reaffirmed 2026 Guidance – And What's Next - simplywall.st
HROW Maintained by Cantor Fitzgerald -- Price Target Lowered to $88 - GuruFocus
Transcript: Harrow Q1 2026 Earnings Conference Call - Sahm
Cantor Fitzgerald Maintains Harrow(HROW.US) With Buy Rating, Cuts Target Price to $88 - Moomoo
HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations - marketscreener.com
Lake Street Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Harrow Health, Inc. (NASDAQ:HROW) Q1 2026 Earnings Call Transcript - Insider Monkey
BTIG Maintains Harrow(HROW.US) With Buy Rating, Maintains Target Price $63 - Moomoo
Harrow stock seeks recovery after plummet - Nashville Post
Harrow Inc (HROW) Q1 2026 Earnings Call Highlights: Strong Product Demand Amid Revenue Challenges - Investing.com Canada
Harrow Stock Tumbles on Weaker 1Q Revenue, Wider Loss - Moomoo
Harrow (HROW) Q1 Loss Of US$27.6 Million Rekindles Profitability Concerns - simplywall.st
Harrow, Inc. (HROW) Reports Q1 2026 Earnings with Positive Outlo - GuruFocus
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):